Niacin/simvastatin: Difference between revisions
Appearance
Content deleted Content added
m misspelling, added link |
m Moving Category:AbbVie brands to Category:Drugs developed by AbbVie per Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands |
||
(20 intermediate revisions by 17 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Combination drug}} |
|||
{{Drugbox |
{{Drugbox |
||
| verifiedrevid = 388938186 |
|||
| type = combo |
| type = combo |
||
| image = Niacinstr.png |
| image = Niacinstr.png |
||
| image2 = Simvastatin.svg |
| image2 = Simvastatin.svg |
||
| component1 = Niacin |
| component1 = Niacin |
||
| class1 = |
| class1 = |
||
| component2 = Simvastatin |
| component2 = Simvastatin |
||
| class2 = [[Statin]] |
| class2 = [[Statin]] |
||
| CAS_number = |
| CAS_number = |
||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
Line 22: | Line 24: | ||
| routes_of_administration = Oral |
| routes_of_administration = Oral |
||
}} |
}} |
||
''' |
'''''' ([[Abbott Laboratories|Abbott]]) is a drug of the drug [[]] and niacin used for the treatment of [[dyslipidemia]]. It was approved by the FDA on February 15, 2008.<ref>{{Cite web|url=://www.drugs.com/newdrugs/abbott-receives-fda-approval-simcor-niaspan-simvastatin-novel-combination-medicine-comprehensive-846.html |title=Drugs.com, Abbott Receives FDA Approval for Simcor (Niaspan / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management |accessdate=2008-03-15 |= }}</ref> |
||
==References== |
==References== |
||
Line 29: | Line 31: | ||
{{Statins}} |
{{Statins}} |
||
{{DEFAULTSORT:Niacin simvastatin}} |
|||
⚫ | |||
[[Category:Drugs developed by AbbVie]] |
|||
{{Cardiovascular-drug-stub}} |
{{Cardiovascular-drug-stub}} |
||
[[Category:Hypolipidemic agents]] |
|||
⚫ |